JP2020533411A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020533411A5 JP2020533411A5 JP2020536493A JP2020536493A JP2020533411A5 JP 2020533411 A5 JP2020533411 A5 JP 2020533411A5 JP 2020536493 A JP2020536493 A JP 2020536493A JP 2020536493 A JP2020536493 A JP 2020536493A JP 2020533411 A5 JP2020533411 A5 JP 2020533411A5
- Authority
- JP
- Japan
- Prior art keywords
- mirna
- mrna sequence
- composition according
- binding site
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004999 messenger RNA Proteins 0.000 claims 16
- 108700011259 MicroRNAs Proteins 0.000 claims 9
- 239000002679 microRNA Substances 0.000 claims 9
- 239000002245 particle Substances 0.000 claims 8
- 244000309459 oncolytic virus Species 0.000 claims 6
- 210000000056 organ Anatomy 0.000 claims 6
- 108091023045 Untranslated Region Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 208000014018 liver neoplasm Diseases 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 241000711404 Avian avulavirus 1 Species 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 241000709698 Coxsackievirus A21 Species 0.000 claims 1
- 241000991587 Enterovirus C Species 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 241000125945 Protoparvovirus Species 0.000 claims 1
- 241000700584 Simplexvirus Species 0.000 claims 1
- 230000002238 attenuated effect Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 108091023663 let-7 stem-loop Proteins 0.000 claims 1
- 108091063478 let-7-1 stem-loop Proteins 0.000 claims 1
- 108091049777 let-7-2 stem-loop Proteins 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 210000005170 neoplastic cell Anatomy 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 208000003265 stomatitis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000007923 virulence factor Effects 0.000 claims 1
- 239000000304 virulence factor Substances 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127023A JP2023159160A (ja) | 2017-09-07 | 2023-08-03 | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス |
| JP2024080380A JP2024122983A (ja) | 2017-09-07 | 2024-05-16 | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1714430.4A GB201714430D0 (en) | 2017-09-07 | 2017-09-07 | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| GB1714430.4 | 2017-09-07 | ||
| US201862632056P | 2018-02-19 | 2018-02-19 | |
| US62/632,056 | 2018-02-19 | ||
| PCT/US2018/049772 WO2019051100A1 (en) | 2017-09-07 | 2018-09-06 | COMPOSITIONS AND METHODS FOR TARGETED CODING ADMINISTRATION, EXPRESSION AND MODULATION OF RIBONUCLEIC ACIDS IN TISSUE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127023A Division JP2023159160A (ja) | 2017-09-07 | 2023-08-03 | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020533411A JP2020533411A (ja) | 2020-11-19 |
| JP2020533411A5 true JP2020533411A5 (enExample) | 2021-10-14 |
Family
ID=60117350
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020536493A Pending JP2020533411A (ja) | 2017-09-07 | 2018-09-06 | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス |
| JP2023127023A Pending JP2023159160A (ja) | 2017-09-07 | 2023-08-03 | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス |
| JP2024015220A Pending JP2024059656A (ja) | 2017-09-07 | 2024-02-02 | コード化リボ核酸の器官保護発現および調節のための組成物および方法 |
| JP2024080380A Pending JP2024122983A (ja) | 2017-09-07 | 2024-05-16 | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127023A Pending JP2023159160A (ja) | 2017-09-07 | 2023-08-03 | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス |
| JP2024015220A Pending JP2024059656A (ja) | 2017-09-07 | 2024-02-02 | コード化リボ核酸の器官保護発現および調節のための組成物および方法 |
| JP2024080380A Pending JP2024122983A (ja) | 2017-09-07 | 2024-05-16 | 組織におけるコード化リボ核酸の標的化送達、発現および調節のための組成物およびプロセス |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11359212B2 (enExample) |
| EP (2) | EP4218770A3 (enExample) |
| JP (4) | JP2020533411A (enExample) |
| KR (1) | KR102741572B1 (enExample) |
| CN (1) | CN111212650A (enExample) |
| AU (1) | AU2018328289B2 (enExample) |
| CA (1) | CA3074293A1 (enExample) |
| ES (1) | ES2942890T3 (enExample) |
| GB (1) | GB201714430D0 (enExample) |
| MX (2) | MX2020002568A (enExample) |
| PL (1) | PL3678673T3 (enExample) |
| PT (1) | PT3678673T (enExample) |
| RU (1) | RU2020112990A (enExample) |
| WO (1) | WO2019051100A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020530454A (ja) | 2017-08-07 | 2020-10-22 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 安全な細胞治療薬を生成するためのプラットフォーム |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| IL295724A (en) * | 2020-02-21 | 2022-10-01 | Combined Therapeutics Inc | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| WO2022035621A1 (en) | 2020-07-31 | 2022-02-17 | Combined Therapeutics, Inc. | Compositions and methods for improved vaccination |
| WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
| CN113444744A (zh) * | 2021-06-28 | 2021-09-28 | 北京鼎成肽源生物技术有限公司 | 一种用于基因编辑NK细胞的mRNA模板及构建方法、mRNA的体外转录方法和应用 |
| CN114107347B (zh) * | 2021-11-24 | 2022-10-28 | 中国人民解放军空军军医大学 | 一种基于具有按需抗炎功能、装载炎症响应型mRNA的工程化外泌体及其构建方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004529607A (ja) * | 2000-09-15 | 2004-09-30 | キュラジェン コーポレイション | ヒトポリヌクレオチドおよびそれによってコードされるポリペプチド |
| EP2140879A1 (en) * | 2001-05-09 | 2010-01-06 | M'S Science Corporation | Composition and method for treating cancer using herpes virus |
| SG179291A1 (en) * | 2003-06-18 | 2012-04-27 | Genelux Corp | Modified recombinant vaccinia viruses and other microorganisms, uses thereof |
| EP1648914A4 (en) | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| WO2009012263A2 (en) | 2007-07-18 | 2009-01-22 | The Trustees Of Columbia University In The City Of New York | Tissue-specific micrornas and compositions and uses thereof |
| MX353900B (es) | 2008-11-07 | 2018-02-01 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| WO2011101912A1 (ja) * | 2010-02-19 | 2011-08-25 | 国立大学法人東京大学 | 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物 |
| EP2763701B1 (en) * | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| KR20140102759A (ko) * | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
| CA2863799C (en) | 2012-02-22 | 2020-09-01 | Matthew J. FRIGAULT | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| CA2892529C (en) * | 2012-11-26 | 2023-04-25 | Moderna Therapeutics, Inc. | Terminally modified rna |
| WO2015058069A1 (en) * | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
| JP6588024B2 (ja) * | 2013-10-28 | 2019-10-09 | ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション | 腫瘍溶解性ｈｓｖベクター |
| CN105848674A (zh) * | 2013-11-11 | 2016-08-10 | 阿尔莫生物科技股份有限公司 | 将白细胞介素-10用于治疗疾病和病症的方法 |
| US20170202979A1 (en) * | 2014-07-17 | 2017-07-20 | Modernatx, Inc. | Terminal modifications of polynucleotides |
| US11351271B2 (en) * | 2014-09-08 | 2022-06-07 | Massachusetts Institute Of Technology | RNA-based logic circuits with RNA binding proteins, aptamers and small molecules |
| WO2016049512A1 (en) * | 2014-09-26 | 2016-03-31 | University Of Massachusetts | Rna-modulating agents |
| WO2016100812A1 (en) * | 2014-12-19 | 2016-06-23 | Moderna Therapeutics, Inc. | Terminal modifications of polynucleotides |
| WO2017013419A1 (en) * | 2015-07-20 | 2017-01-26 | Virttu Biologics Limited | Use of oncolytic herpes simplex virus, alone or in combination with immune checkpoint inhibitor, in the treatment of cancer |
| CA3001003A1 (en) * | 2015-10-05 | 2017-04-13 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| CN108474003A (zh) * | 2015-11-20 | 2018-08-31 | 俄勒冈健康与科学大学 | 包含微小rna识别元件的cmv载体 |
| EP4089166A1 (en) * | 2016-01-27 | 2022-11-16 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| RU2765874C2 (ru) | 2016-10-26 | 2022-02-04 | МОДЕРНАТиЭкс, ИНК. | Матричные рибонуклеиновые кислоты для усиления иммунных ответов и способы их применения |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| GB201714430D0 (en) | 2017-09-07 | 2017-10-25 | Micol Romain | Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue |
| EP4008333A1 (en) | 2018-02-19 | 2022-06-08 | Combined Therapeutics, Inc. | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
| IL295724A (en) * | 2020-02-21 | 2022-10-01 | Combined Therapeutics Inc | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids |
-
2017
- 2017-09-07 GB GBGB1714430.4A patent/GB201714430D0/en not_active Ceased
-
2018
- 2018-09-06 ES ES18792572T patent/ES2942890T3/es active Active
- 2018-09-06 EP EP23153161.7A patent/EP4218770A3/en active Pending
- 2018-09-06 MX MX2020002568A patent/MX2020002568A/es unknown
- 2018-09-06 CA CA3074293A patent/CA3074293A1/en active Pending
- 2018-09-06 JP JP2020536493A patent/JP2020533411A/ja active Pending
- 2018-09-06 EP EP18792572.2A patent/EP3678673B1/en active Active
- 2018-09-06 RU RU2020112990A patent/RU2020112990A/ru unknown
- 2018-09-06 WO PCT/US2018/049772 patent/WO2019051100A1/en not_active Ceased
- 2018-09-06 KR KR1020207009937A patent/KR102741572B1/ko active Active
- 2018-09-06 PT PT187925722T patent/PT3678673T/pt unknown
- 2018-09-06 PL PL18792572.2T patent/PL3678673T3/pl unknown
- 2018-09-06 CN CN201880066146.2A patent/CN111212650A/zh active Pending
- 2018-09-06 AU AU2018328289A patent/AU2018328289B2/en active Active
-
2019
- 2019-02-19 MX MX2020008606A patent/MX2020008606A/es unknown
-
2020
- 2020-03-06 US US16/811,504 patent/US11359212B2/en active Active
-
2022
- 2022-03-28 US US17/706,522 patent/US12195746B2/en active Active
-
2023
- 2023-08-03 JP JP2023127023A patent/JP2023159160A/ja active Pending
-
2024
- 2024-02-02 JP JP2024015220A patent/JP2024059656A/ja active Pending
- 2024-05-16 JP JP2024080380A patent/JP2024122983A/ja active Pending
- 2024-12-17 US US18/984,898 patent/US20250129383A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020533411A5 (enExample) | ||
| Das et al. | Gene therapies for cancer: strategies, challenges and successes | |
| Wei et al. | Fighting cancer with viruses: oncolytic virus therapy in China | |
| Chiocca et al. | Oncolytic viruses and their application to cancer immunotherapy | |
| JP5448840B2 (ja) | 腫瘍退縮アデノウイルスの作出およびその使用 | |
| Zhu et al. | Development and application of oncolytic viruses as the nemesis of tumor cells | |
| Malhotra et al. | Oncolytic viruses and cancer immunotherapy | |
| US11596685B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| Burton et al. | Syncytia formation in oncolytic virotherapy | |
| JP5943996B2 (ja) | 腫瘍溶解性強化Ｂ型ヒトアデノウイルスＡｄ１１突然変異体の構築とその応用 | |
| JP2019517815A5 (enExample) | ||
| Chai et al. | Oncolytic therapy of a recombinant Newcastle disease virus D90 strain for lung cancer | |
| Parsel et al. | Nucleic acid targeting: towards personalized therapy for head and neck cancer | |
| JP2014523236A5 (enExample) | ||
| Bin Liu et al. | Virus, oncolytic virus and human prostate cancer | |
| Wei et al. | Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors | |
| Li et al. | A recombinant oncolytic influenza virus carrying GV1001 triggers an antitumor immune response | |
| Toropko et al. | miRNA-mediated mechanisms in the generation of effective and safe oncolytic viruses | |
| US11739350B2 (en) | MicroRNA-based compositions and methods used in disease treatment | |
| Ulasov et al. | Oncolytic adenoviruses: a thorny path to glioma cure | |
| WO2023020556A1 (zh) | 病毒制剂、用于配制病毒制剂的溶液及其用途 | |
| JPWO2019158955A5 (enExample) | ||
| Kueberuwa et al. | Tissue-specific attenuation of oncolytic sindbis virus without compromised genetic stability | |
| Courchesne et al. | Equine herpesvirus type 1-mediated oncolysis of human glioblastoma multiforme cells | |
| Fu et al. | Potential adenovirus-mediated gene therapy of glioma cancer |